Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
albumin-bound paclitaxel + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination chemotherapy regimen consisting of albumin-bound paclitaxel (nab-paclitaxel) and oxaliplatin. Albumin-bound paclitaxel is a nanoparticle formulation of the microtubule inhibitor paclitaxel, which allows for solvent-free delivery and improved tolerability. Oxaliplatin is a platinum-based chemotherapeutic that induces DNA crosslinking and apoptosis in cancer cells. The combination has been investigated primarily in gastrointestinal cancers, including advanced gastric cancer and upper gastrointestinal cancers, often alongside S-1 or leucovorin as part of multi-drug regimens[8]. Nab-paclitaxel disrupts microtubule function by stabilizing tubulin polymers, leading to cell cycle arrest at the G2/M phase; oxaliplatin forms DNA adducts that inhibit DNA replication and transcription, resulting in cell death.
- Other names
- nab-paclitaxel + oxaliplatinnanoparticle albumin-bound paclitaxel + oxaliplatin
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on albumin-bound paclitaxel + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on albumin-bound paclitaxel + oxaliplatin.